Ensysce Biosciences, Inc.
ENSC
Rank in Stocks
#29647
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Share Price
$0.3872
Last synced: 2026-11-12
Market Cap
$7.04M
Change (1 day)
7.53%
Change (1 year)
-81.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ensysce Biosciences, Inc. (ENSC)
Category
Healthcare
EPS for Ensysce Biosciences, Inc. (ENSC)
EPS as of September 2026 TTM: $-5.99
According to Ensysce Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-5.99. At the end of 2025 the company had an EPS of $-3.98, an increase over its 2024 EPS of $-4.57.
EPS history for Ensysce Biosciences, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-5.99 | 50.50% |
| 2025 | $-3.98 | -12.91% |
| 2024 | $-4.57 | -2.56% |
| 2023 | $-4.69 | -96.64% |
| 2022 | $-139.44 | -60.80% |
| 2021 | $-355.68 | -63,614.29% |
| 2020 | $0.56 | -133.73% |
| 2019 | $-1.66 | 654.55% |
| 2018 | $-0.22 | 4,130.77% |
| 2017 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -85.14% |
US
|
|
| $15.66 | -361.44% |
US
|
|
| $-7.07 | 18.03% |
US
|
|
| $-5.29 | -11.69% |
AU
|
|
| $12.73 | -312.56% |
BE
|
Questions about Ensysce Biosciences, Inc.'s earnings per share (EPS)
What is Ensysce Biosciences, Inc.'s earnings per share (EPS)?
Ensysce Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-5.99, as of Sep 2026.
What was Ensysce Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Ensysce Biosciences, Inc.'s earnings per share (EPS) was $-3.98, compared with $-4.57 in 2024.
How has Ensysce Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Ensysce Biosciences, Inc.'s earnings per share (EPS) was highest in 2020 ($0.56) and lowest in 2021 ($-355.68).
How does Ensysce Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Ensysce Biosciences, Inc.'s earnings per share (EPS) ($-5.99) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.